•
German pharmaceutical major Boehringer Ingelheim (BI) has entered into a partnership with China-based Sinopharm Group Co., Ltd (HKG: 1099), granting the latter the rights to promote Boehringer Ingelheim’s Sifrol (pramipexole) and Pradaxa (dabigatran) in China effective from January 1, 2025. Boehringer Ingelheim will retain ownership and manufacturing responsibilities for both…
•
Sinopharm Holding (HKG: 1099) has announced significant changes in its leadership with the approval of its board of directors for the appointment of Zhao Bingxiang as the new chairman and Lian Wanyong as the president. This comes as former chairman Yu Qingming and president Liu Yong have stepped down from…
•
China’s state-owned Sinopharm Group Co., Ltd. (HKG: 1099) has announced a new partnership with Germany’s Fresenius Kabi, enhancing collaboration across various sectors including drug sales, warehousing and distribution, as well as big health, medical care, and wellness. Financial details of the agreement were not disclosed. This partnership marks a continuation…
•
China Traditional Medicine Holdings (HKG: 0570; China TCM) has announced that its controlling shareholder, the state-owned Sinopharm Group Co., Ltd (HKG: 1099), intends to take the company private. The proposed deal values China TCM at a price of HKD 4.6 per share, representing a 34% premium over the recent closing…
•
Fosun Kite and Medi Cover, a health management and patient service platform under Sinopharm (HKG: 1099), have jointly introduced the first value-based payment (VBP) plan for lymphoma associated with Fosun Kite’s chimeric antigen receptor (CAR) T cell therapy, Yescarta (axicabtagene ciloleucel). Under this innovative plan, eligible patients who do not…
•
Youcare Pharmaceutical Group (SHA: 688658), a China-based pharmaceutical company, has entered into a partnership with Sinopharm Group Heilongjiang Co., Ltd., a major player in China’s pharmaceutical distribution sector. This collaboration is aimed at expanding Youcare’s market reach and resource pool, leveraging Sinopharm’s (HKG: 1099) extensive distribution channels and resource advantages.…
•
US pharmaceutical giant AbbVie (NYSE: ABBV) has entered into a strategic partnership with Sinopharm Group Co., Ltd, (HKG: 1099) a leading Chinese pharmaceutical company, to improve access to novel drugs and explore standardized patient management practices in China. Expanding Access and Patient SupportThe collaboration will utilize Sinopharm’s extensive SPS+ professional…